No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GRFS240719P15000
- 0.00
- 0.000.00%
15min DelayClose Jul 1 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover292.21%IV-138.85%PremiumJul 19, 2024Expiry Date8.72Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8443Delta0.0598Gamma0.70Leverage Ratio-0.0251Theta-0.0050Rho-0.59Eff Leverage0.0034Vega
Intraday
- 5D
- Daily
No Data
News
Grifols' Biotest Set to Launch Intravenous Immunoglobulin in US in Q1 2025
Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Grifols Says At End June 2024, Considering SRAAS Proceeds, Leverage Ratio Is Expected To Reach 5.4x Vs. 6.8x In March 2024; FCF In Q2 2024 Expected To Be Positive, Contributing To Reach €5 Million FY24 Guidance, Which Includes €480 Million Of...
Grifols Says €1.6 Billion Net Cash Proceeds From Sale Of 20% Equity Stake In Shanghai RAAS Are Currently Deposited In Co's Bank Account; Proceeds Will Be Fully Allocated To Reduce 2025 Senior Secured Notes And 2027 Term Loan B And On A Pro-Rata Basis...
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Grifols Leads Three Stocks That May Be Priced Below Their Estimated True Value
Comments
$Grifols(GRFS.US$ Grifols Says €1.6 Billion Net Cash Proceeds From Sale Of 20% Equity Stake In Shanghai RAAS Are Currently Deposited In Co's Bank Account; Proceeds Will Be Fully Allocated To Reduce 2025 Senior Secured Notes And 2027 Term Loan B And On A Pro-Rata Basis As Per Credit Agreement; To Repay In Full 2025 Debt Maturities, Leaving No Additional Maturities Until 2027
- Reuters
- Reuters
$Grifols(GRFS.US$ Grifols' Subsidiary Biotest Receives FDA Approval For Yimmugo, An Intravenous Immunoglobulin Therapeutic, To Treat Primary Immunodeficiencies, With US Launch Expected In Second Part Of 2024
Benzinga· 1 min ago
Benzinga· 1 min ago
1
1
$Grifols(GRFS.US$ Notorious Short seller GOTHAM spread FUD and crashes price a few weeks back! And then others keep posting the hit piece! But you hardly see any stories that GRIFOLS has filed a lawsuit against GOTHAM for that accusation! Grrrr! Well here GOTHAM, take this! Not great but good start! At least IMO! (((((((((. Grifols Q1 Net Revenues €1.63 Billion Vs €1.56 Billion YoY; Sees Q1 R&D Negative Net Investment €90.5 M...
$Grifols(GRFS.US$ MT Newswires· 3 mins ago
Grifols (GRF.MC) said Monday that the sale of its 20% stake in blood products company Shanghai RAAS to Chinese home appliance company Haier Group is expected to be completed by June.
The Spanish pharmaceutical company said both the buyer and seller secured the necessary domestic and overseas government approvals for the deal. It noted that the transaction still requires a compliance confirmation from the Shenzhen Stock Exchange.
Grifols (GRF.MC) said Monday that the sale of its 20% stake in blood products company Shanghai RAAS to Chinese home appliance company Haier Group is expected to be completed by June.
The Spanish pharmaceutical company said both the buyer and seller secured the necessary domestic and overseas government approvals for the deal. It noted that the transaction still requires a compliance confirmation from the Shenzhen Stock Exchange.
$Grifols(GRFS.US$ April 22, 2024 Grifols achieves positive results from phase 4 study of Fanhdi® (double-inactivated human anti-hemophilic factor) in patients with von Willebrand Disease Download PDF Grifols’ Fanhdi showed it could be effective, safe and well tolerated in the management of bleeding episodes and for the prevention of bleeding during surgeries in patients with von Willebrand Disease (VWD) VWD, which is caused by a deficiency of von Willebrand factor in plasma, is the most common ...
Read more